Sustainability Key To ABL Bio’s Journey From ‘Good To Great’
Goal To Become An R&D-Focused Subsidiary
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
